share_log

EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30

EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30

EF Hutton启动对ImmunityBio的覆盖,给予买入评级,公布目标价格为30美元
Benzinga ·  10/23 19:11  · 评级/大行评级

EF Hutton analyst Jason Kolbert initiates coverage on ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Price Target of $30.

EF Hutton的分析师Jason Kolbert开始对ImmunityBio(纳斯达克:IBRX)进行覆盖,给予买入评级,并公布目标股价为30美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发